|
| 33082209 | Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors. | Clin Cancer Res | 2021 |
| 33928209 | Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. | JCO Precis Oncol | 2021 |
| 33082209 | Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors. | Clin Cancer Res | 2021 |
| 34592177 | Inappropriate censoring in Kaplan-Meier analyses. | Lancet Oncol | 2021 |
| 33928209 | Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. | JCO Precis Oncol | 2021 |
| 34592177 | Inappropriate censoring in Kaplan-Meier analyses. | Lancet Oncol | 2021 |
| 31304851 | Finding the intended use population for a new treatment. | J Biopharm Stat | 2019 |
| 31757478 | A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. | Semin Oncol | 2019 |
| 35100721 | Review of Statistical Methods for Biomarker-Driven Clinical Trials. | JCO Precis Oncol | 2019 |
| 31272507 | Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. | J Immunother Cancer | 2019 |
| 31367787 | Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines. | Cancer Chemother Pharmacol | 2019 |
| 31304851 | Finding the intended use population for a new treatment. | J Biopharm Stat | 2019 |
| 35100721 | Review of Statistical Methods for Biomarker-Driven Clinical Trials. | JCO Precis Oncol | 2019 |
| 31757478 | A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. | Semin Oncol | 2019 |
| 31272507 | Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. | J Immunother Cancer | 2019 |
| 31367787 | Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines. | Cancer Chemother Pharmacol | 2019 |
| 28520893 | Using Bayesian modeling in frequentist adaptive enrichment designs. | Biostatistics | 2018 |
| 28877003 | New designs for basket clinical trials in oncology. | J Biopharm Stat | 2018 |
| 28520893 | Using Bayesian modeling in frequentist adaptive enrichment designs. | Biostatistics | 2018 |
| 30355619 | The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel. | Cancer Res | 2018 |
| 30652557 | D3Oncoprint: Stand-Alone Software to Visualize and Dynamically Explore Annotated Genomic Mutation Files. | JCO Clin Cancer Inform | 2018 |
| 29642934 | Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment. | Hum Genomics | 2018 |
| 30652557 | D3Oncoprint: Stand-Alone Software to Visualize and Dynamically Explore Annotated Genomic Mutation Files. | JCO Clin Cancer Inform | 2018 |
| 30355619 | The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel. | Cancer Res | 2018 |
| 29642934 | Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment. | Hum Genomics | 2018 |
| 28877003 | New designs for basket clinical trials in oncology. | J Biopharm Stat | 2018 |
| 27422621 | OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials. | Brief Bioinform | 2017 |
| 28498733 | Immunotherapy is different: Implications for vaccine clinical trial design. | Hum Vaccin Immunother | 2017 |
| 28795420 | Inference for multimarker adaptive enrichment trials. | Stat Med | 2017 |
| 28795401 | Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials. | Clin Pharmacol Ther | 2017 |
| 29162114 | A computational study of the inhibition mechanisms of P-glycoprotein mediated paclitaxel efflux by kinase inhibitors. | BMC Syst Biol | 2017 |
| 29245008 | On the Design of Combination Cancer Therapy. | Cell | 2017 |
| 29276373 | Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents. | Cancer Inform | 2017 |
| 27422621 | OpenGeneMed: a portable, flexible and customizable informatics hub for the coordination of next-generation sequencing studies in support of precision medicine trials. | Brief Bioinform | 2017 |
| 27979599 | Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. | Lancet Oncol | 2017 |
| 27582434 | Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. | J Urol | 2017 |
| 28498733 | Immunotherapy is different: Implications for vaccine clinical trial design. | Hum Vaccin Immunother | 2017 |
| 29276373 | Longitudinal Transcriptional Response of Glycosylation-Related Genes, Regulators, and Targets in Cancer Cell Lines Treated With 11 Antitumor Agents. | Cancer Inform | 2017 |
| 29245008 | On the Design of Combination Cancer Therapy. | Cell | 2017 |
| 29162114 | A computational study of the inhibition mechanisms of P-glycoprotein mediated paclitaxel efflux by kinase inhibitors. | BMC Syst Biol | 2017 |
| 28795420 | Inference for multimarker adaptive enrichment trials. | Stat Med | 2017 |
| 28795401 | Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials. | Clin Pharmacol Ther | 2017 |
| 27979599 | Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. | Lancet Oncol | 2017 |
| 27582434 | Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. | J Urol | 2017 |
| 26970120 | The Bayesian basket design for genomic variant-driven phase II trials. | Semin Oncol | 2016 |
| 27347216 | Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment. | Clin Epigenetics | 2016 |
| 26970120 | The Bayesian basket design for genomic variant-driven phase II trials. | Semin Oncol | 2016 |
| 27130933 | Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. | J Natl Cancer Inst | 2016 |
| 27214515 | Genomic Alteration-Driven Clinical Trial Designs in Oncology. | Ann Intern Med | 2016 |
| 26602013 | Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. | J Mol Diagn | 2016 |